Nanobody Therapeutics Market Size, Share & Industry Analysis, By Molecule (Caplacizumab (Cablivi), Ozoralizumab (Nanozora), Envafolimab, and Others), By Nanobody Type (Bivalent, Trivalent, Fc-fused / Half-life Extended, and Others), By Disease Indication (Hematological / Blood Disorders, Rheumatoid Arthritis, Oncology, and Others) By Route of Administration (Intravenous, Subcutaneous, and Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated: April 08, 2026 | Format: PDF | Report ID: FBI115882

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Technological Advancements in Nanobody Therapeutics
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, among others.)
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Regions
5. Pipeline Analysis, By Key Players
Global Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Rest of the World Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Sanofi
  2. 3D Medicines Inc.
  3. Taisho Pharmaceutical Co., Ltd.
  4. Other Prominent Players

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Technological Advancements in Nanobody Therapeutics
2. Key Industry Developments (Mergers, Acquisitions, Partnerships, among others.)
3. New Product Launches, By Key Players
4. Regulatory Scenario, By Key Countries/Regions
5. Pipeline Analysis, By Key Players
Global Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Rest of the World
North America Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. U.K.
  2. Germany
  3. France
  4. Italy
  5. Spain
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
6. Market Analysis, Insights and Forecast – By Country/ Sub-Region
  1. China
  2. Japan
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Rest of the World Nanobody Therapeutics Market Analysis, Insights and Forecast, 2021-2034
1. Market Analysis, Insights and Forecast – By Molecule
  1. Caplacizumab (Cablivi)
  2. Ozoralizumab (Nanozora)
  3. Envafolimab
  4. Others
2. Market Analysis, Insights and Forecast – By Nanobody Type
  1. Bivalent
  2. Trivalent
  3. Fc-fused / Half-life extended
  4. Others
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Hematological / Blood Disorders
  2. Rheumatoid Arthritis
  3. Oncology
  4. Others
4. Market Analysis, Insights and Forecast – By Route of Administration
  1. Intravenous
  2. Subcutaneous
  3. Others
5. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacies
  2. Specialty Pharmacies
  3. Others
Competitive Analysis
1. Global Market Share Analysis (2025)
2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
  1. Sanofi
  2. 3D Medicines Inc.
  3. Taisho Pharmaceutical Co., Ltd.
  4. Other Prominent Players

Read Less

List of Figures

Figure 1: Global Nanobody Therapeutics Market Revenue Breakdown (USD Million, %) by Region, 2025 & 2034

Figure 2: Global Nanobody Therapeutics Market Value Share (%), By Molecule, 2025 & 2034

Figure 3: Global Nanobody Therapeutics Market Value Share (%), By Nanobody Type, 2025 & 2034

Figure 4: Global Nanobody Therapeutics Market Value Share (%), By Disease Indication, 2025 & 2034

Figure 5: Global Nanobody Therapeutics Market Value Share (%), By Route of Administration, 2025 & 2034

Figure 6: Global Nanobody Therapeutics Market Value Share (%), By Distribution Channel, 2025 & 2034

Figure 7: Global Nanobody Therapeutics Market Value Share (%), by Region, 2025 & 2034

Figure 8: North America Nanobody Therapeutics Market Value (USD Million), By Molecule, 2025 & 2034

Figure 9: North America Nanobody Therapeutics Market Value Share (%), By Molecule, 2025

Figure 10: North America Nanobody Therapeutics Market Value (USD Million), By Nanobody Type, 2025 & 2034

Figure 11: North America Nanobody Therapeutics Market Value Share (%), By Nanobody Type, 2025

Figure 12: North America Nanobody Therapeutics Market Value (USD Million), By Disease Indication, 2025 & 2034

Figure 13: North America Nanobody Therapeutics Market Value Share (%), By Disease Indication, 2025

Figure 14: North America Nanobody Therapeutics Market Value (USD Million), By Route of Administration, 2025 & 2034

Figure 15: North America Nanobody Therapeutics Market Value Share (%), By Route of Administration, 2025

Figure 16: North America Nanobody Therapeutics Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 17: North America Nanobody Therapeutics Market Value Share (%), By Distribution Channel, 2025

Figure 18: North America Nanobody Therapeutics Market Value (USD Million), by Country, 2025 & 2034

Figure 19: North America Nanobody Therapeutics Market Value Share (%), by Country, 2025

Figure 20: Europe Nanobody Therapeutics Market Value (USD Million), By Molecule, 2025 & 2034

Figure 21: Europe Nanobody Therapeutics Market Value Share (%), By Molecule, 2025

Figure 22: Europe Nanobody Therapeutics Market Value (USD Million), By Nanobody Type, 2025 & 2034

Figure 23: Europe Nanobody Therapeutics Market Value Share (%), By Nanobody Type, 2025

Figure 24: Europe Nanobody Therapeutics Market Value (USD Million), By Disease Indication, 2025 & 2034

Figure 25: Europe Nanobody Therapeutics Market Value Share (%), By Disease Indication, 2025

Figure 26: Europe Nanobody Therapeutics Market Value (USD Million), By Route of Administration, 2025 & 2034

Figure 27: Europe Nanobody Therapeutics Market Value Share (%), By Route of Administration, 2025

Figure 28: Europe Nanobody Therapeutics Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 29: Europe Nanobody Therapeutics Market Value Share (%), By Distribution Channel, 2025

Figure 30: Europe Nanobody Therapeutics Market Value (USD Million), by Country/ Sub-region, 2025 & 2034

Figure 31: Europe Nanobody Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 32: Asia Pacific Nanobody Therapeutics Market Value (USD Million), By Molecule, 2025 & 2034

Figure 33: Asia Pacific Nanobody Therapeutics Market Value Share (%), By Molecule, 2025

Figure 34: Asia Pacific Nanobody Therapeutics Market Value (USD Million), By Nanobody Type, 2025 & 2034

Figure 35: Asia Pacific Nanobody Therapeutics Market Value Share (%), By Nanobody Type, 2025

Figure 36: Asia Pacific Nanobody Therapeutics Market Value (USD Million), By Disease Indication, 2025 & 2034

Figure 37: Asia Pacific Nanobody Therapeutics Market Value Share (%), By Disease Indication, 2025

Figure 38: Asia Pacific Nanobody Therapeutics Market Value (USD Million), By Route of Administration, 2025 & 2034

Figure 39: Asia Pacific Nanobody Therapeutics Market Value Share (%), By Route of Administration, 2025

Figure 40: Asia Pacific Nanobody Therapeutics Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 41: Asia Pacific Nanobody Therapeutics Market Value Share (%), By Distribution Channel, 2025

Figure 42: Asia Pacific Nanobody Therapeutics Market Value (USD Million), by Country/ Sub-region, 2025 & 2034

Figure 43: Asia Pacific Nanobody Therapeutics Market Value Share (%), by Country/ Sub-region, 2025

Figure 44: Rest of the World Nanobody Therapeutics Market Value (USD Million), By Molecule, 2025 & 2034

Figure 45: Rest of the World Nanobody Therapeutics Market Value Share (%), By Molecule, 2025

Figure 46: Rest of the World Nanobody Therapeutics Market Value (USD Million), By Nanobody Type, 2025 & 2034

Figure 47: Rest of the World Nanobody Therapeutics Market Value Share (%), By Nanobody Type, 2025

Figure 48: Rest of the World Nanobody Therapeutics Market Value (USD Million), By Disease Indication, 2025 & 2034

Figure 49: Rest of the World Nanobody Therapeutics Market Value Share (%), By Disease Indication, 2025

Figure 50: Rest of the World Nanobody Therapeutics Market Value (USD Million), By Route of Administration, 2025 & 2034

Figure 51: Rest of the World Nanobody Therapeutics Market Value Share (%), By Route of Administration, 2025

Figure 52: Rest of the World Nanobody Therapeutics Market Value (USD Million), By Distribution Channel, 2025 & 2034

Figure 53: Rest of the World Nanobody Therapeutics Market Value Share (%), By Distribution Channel, 2025

Figure 54: Global Nanobody Therapeutics Market Share (%), by Company, 2025

List of Tables

Table 1: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Molecule, 2021-2034

Table 2: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Nanobody Type, 2021-2034

Table 3: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Disease Indication, 2021-2034

Table 4: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Route of Administration, 2021-2034

Table 5: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Distribution Channel, 2021-2034

Table 6: Global Nanobody Therapeutics Market Revenue (USD Million) Forecast, by Region, 2021-2034

Table 7: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Molecule, 2021-2034

Table 8: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Nanobody Type, 2021-2034

Table 9: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Disease Indication, 2021-2034

Table 10: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Route of Administration, 2021-2034

Table 11: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Distribution Channel, 2021-2034

Table 12: North America Nanobody Therapeutics Market Revenue (USD Million) Forecast, by Country, 2021-2034

Table 13: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Molecule, 2021-2034

Table 14: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Nanobody Type, 2021-2034

Table 15: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Disease Indication, 2021-2034

Table 16: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Route of Administration, 2021-2034

Table 17: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Distribution Channel, 2021-2034

Table 18: Europe Nanobody Therapeutics Market Revenue (USD Million) Forecast, by Country/ Sub-region, 2021-2034

Table 19: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Molecule, 2021-2034

Table 20: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Nanobody Type, 2021-2034

Table 21: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Disease Indication, 2021-2034

Table 22: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Route of Administration, 2021-2034

Table 23: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Distribution Channel, 2021-2034

Table 24: Asia Pacific Nanobody Therapeutics Market Revenue (USD Million) Forecast, by Country/ Sub-region, 2021-2034

Table 25: Rest of the World Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Molecule, 2021-2034

Table 26: Rest of the World Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Nanobody Type, 2021-2034

Table 27: Rest of the World Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Disease Indication, 2021-2034

Table 28: Rest of the World Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Route of Administration, 2021-2034

Table 29: Rest of the World Nanobody Therapeutics Market Revenue (USD Million) Forecast, By Distribution Channel, 2021-2034

STUDY PERIOD: 2021-2034
BASE YEAR: 2025
HISTORICAL DATA: 2021-2024
NO OF PAGES: 164

Buy Now

Download Free Sample

Security Code

Get 20% Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

(APAC) +91 744 740 1245
sales@fortunebusinessinsights.com